The DOI matches its Crossref record.
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
Open accessAbstract
Patients with previously untreated squamous cell lung carcinomas were evaluated to see if combining the expression of molecular and cellular factors with the most important clinical prognostic factors could improve the diagnostic ability to predict prognosis. For this reason, immunohistochemistry was used to examine the squamous cell lung carcinomas from 121 patients for their expression of ERBB-1, vascular endothelial growth factor (VEGF), cyclin A, FOS, JUN and MYC. Median survival was shorter for patients with ERBB-1-, VEGF-, cyclin A-, FOS-, or JUN-positive tumours. For those patients with positive lymph node involvement, the survival times were also shorter in the VEGF-positive, cyclin A-positive and FOS-positive groups. Multivariate analysis independently demonstrated a significant prognostic value for lymph node involvement, VEGF and FOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Di Maria, M. V., Veve, R., Bremnes, R. M., Barón, A. E., Zeng, C., & Franklin, W. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.069 · Cited by 1,477
Review of epidermal growth factor receptor biology
Herbst, R. S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.11.041 · Cited by 1,390
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 827
The Fos family of transcription factors and their role in tumourigenesis
Milde-Langosch, K. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.008 · Cited by 583
Herbst, R. S., Maddox, A.-M., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.038 · Cited by 572
Prognostic Factors in Non-small Cell Lung Cancer
Brundage, M. D., Davies, D., & Mackillop, W. J. (2002) · Chest · doi:10.1378/chest.122.3.1037 · Cited by 564
Cyclin A in cell cycle control and cancer
Yam, C. H., Fung, T. K., & Poon, R. Y. C. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8510-y · Cited by 520
Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?
Arteaga, C. L. (2002) · The Oncologist · doi:10.1634/theoncologist.7-2004-31 · Cited by 455
Herbst, R. S., & Shin, D. M. (2002) · Cancer · doi:10.1002/cncr.10372 · Cited by 446
Jänne, P. A., Engelman, J. A., & Johnson, B. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.985 · Cited by 405
Epidermal growth factor receptor family in lung cancer and premalignancy
Franklin, W. A., Veve, R., Hirsch, F. R., Helfrich, B. A., & Bunn, P. A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31520 · Cited by 306
Singhal, S., Vachani, A., Antin-Ozerkis, D., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2661 · Cited by 295
Meert, A.-P., Martin, B., Delmotte, P., Berghmans, T., Lafitte, J.-J., Mascaux, C., Paesmans, M., Steels, E., Verdebout, J.-M., & Sculier, J.-P. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00296502 · Cited by 264
Epidermal growth factor receptor: a promising target in solid tumours
Laskin, J. J., & Sandler, A. B. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.10.002 · Cited by 253
Biomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making
Scott, A., & Salgia, R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.6.577 · Cited by 59
Metadata
- Authors
- Volm, M., Rittgen, W., & Drings, P.
- Venue
- British Journal of Cancer
- Published
- 1998-02-01
- Volume
- 77
- Issue
- 4
- Pages
- 663-669
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2019995422
- Cited by
- 178
- References
- 0
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.